🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting more than 82 million new cases annually. Notably increased rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the face of growing infection rates, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This medication, which is also used to treat urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to develop it.

“This milestone marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Testing Data and Worldwide Availability

Based on data published in a prominent scientific publication, the new drug cured over nine in ten of cases of the STI. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The research enrolled hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Medical professionals on the front lines have shared positive views. The availability of a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the infection for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.